Key facts
- This page summarizes Kaitlyn Arsenault's Form 4/A - Amendment filing for Skye Bioscience, Inc. (SKYE).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Feb 2025, 18:54.
Kaitlyn Arsenault - 15 Nov 2024 Form 4/A - Amendment Insider Report for Skye Bioscience, Inc. (SKYE)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- SKYE
- Reported as of
- 15 Nov 2024
- Net transaction value
- -$215,754
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 28 Feb 2025, 18:54:45 UTC
- Original report date
- 19 Nov 2024
- Prior SEC filing
- 30 Oct 2024
- Next SEC filing
- 26 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kaitlyn Arsenault
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Kaitlyn Arsenault filed Form 4/A - Amendment for Skye Bioscience, Inc. (SKYE) on 28 Feb 2025.
Change
- Previous filing in this sequence was filed on 30 Oct 2024.
- Current net transaction value: -$215,754.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SKYE
transaction
Common Stock
Sale
- Transaction value
- $1,054
- Shares
- -190
- Change %
- -0.09%
- Price
- $5.55
- Shares after
- 210,548
- Date
- 15 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
SKYE
transaction
Common Stock
Sale
- Transaction value
- $214,700
- Shares
- -43,026
- Change %
- -20%
- Price
- $4.99
- Shares after
- 167,522
- Date
- 18 Nov 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person.
Footnote F2
The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.
SEC remarks
This amendment is being filed to correct an inadvertent typographical error in the Original Form 4 in which the number of shares held by the Reporting Person following the transaction was reported as 166,342 instead of 167,522.